How to Get Lantus (Insulin Glargine) in Nevada

What Is Lantus and Why Is It Prescribed?

Insulin glargine is a long-acting basal insulin analog that provides a relatively flat, peakless 24-hour glucose-lowering profile after a single subcutaneous injection. Sanofi's branded product Lantus (insulin glargine 100 U/mL) was the first glargine formulation approved by the FDA and remains one of the most prescribed basal insulins in the United States [1]. The drug is indicated for adults and pediatric patients (age 6 and older) with type 1 diabetes mellitus, and for adults with type 2 diabetes mellitus who need basal insulin to achieve glycemic targets set by the American Diabetes Association [2].

The landmark ORIGIN trial (N=12,537) published in the New England Journal of Medicine in 2012 compared insulin glargine to standard care in people with dysglycemia. After a median follow-up of 6.2 years, glargine produced a median A1C of 6.2% versus 6.5% in the standard-care group, and it did not increase rates of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (hazard ratio 1.02; 95% CI 0.94, 1.11; P<0.001 for non-inferiority) [3]. That long-term cardiovascular safety dataset is why many endocrinologists consider glargine a well-characterized option when initiating basal insulin.

The FDA-approved label specifies starting doses of 0.1, 0.2 units/kg/day for type 2 diabetes naive to insulin, titrated to a fasting glucose target of 80 to 130 mg/dL per ADA Standards of Care [4]. Dose titration is typically done in 2-unit increments every 3 days based on fasting self-monitored blood glucose [2].

Who Can Prescribe Lantus in Nevada?

Any Nevada-licensed prescriber with Schedule III, V prescriptive authority can write a valid Lantus prescription. That group includes medical doctors (MD), doctors of osteopathic medicine (DO), nurse practitioners (APRN-CNP), physician assistants (PA-C), and clinical pharmacist practitioners who hold collaborative practice agreements under Nevada Revised Statutes Chapter 639 [5]. Endocrinologists, primary care physicians, and internal medicine physicians are the most common prescribers for basal insulin, but an APRN in a rural Nevada clinic or a telehealth PA-C working under a supervising physician can also initiate and manage glargine therapy.

Nevada law does not require an in-person visit before issuing a prescription for a non-controlled medication such as insulin. The Nevada State Board of Pharmacy and the Nevada State Board of Medical Examiners both permit telehealth-based prescribing when the provider can establish a valid patient-provider relationship, which typically requires a synchronous video or audio-video encounter, a review of medical history, and documentation of clinical findings [5].

Specialists to consider by geography:

• Las Vegas and Henderson: University Medical Center Diabetes Center, Desert Endocrinology, and several large primary care groups all prescribe glargine routinely.
• Reno and Sparks: Renown Health Endocrinology and multiple independent internal medicine practices.
• Rural Nevada: Federally Qualified Health Centers (FQHCs) such as Nevada Health Centers, Inc., operate across Elko, Fallon, and Winnemucca and can prescribe insulin under sliding-scale or grant-funded programs [6].

How to Get a Lantus Prescription Through Telehealth in Nevada

Nevada permits telehealth prescribing of non-controlled drugs, which makes insulin glargine an eligible medication for a fully remote encounter. The process runs in five concrete steps.

Step 1. Book a synchronous video visit. Platforms licensed to see Nevada patients include HealthRX, Teladoc, MDLive, and Sesame Care, among others. Verify that the provider holds an active Nevada medical license before scheduling.

Step 2. Prepare your records. Bring your most recent A1C (drawn within the past 90 days is ideal), a fasting plasma glucose log if available, a list of current medications, and any prior diabetes diagnoses or hospital records. The ADA Standards of Care recommend an A1C target of <7% for most non-pregnant adults, and your provider will use your current A1C to calibrate starting dose [2].

Step 3. Complete the clinical interview. The provider will review your diabetes history, current glycemic control, renal function (glargine dose may need adjustment if eGFR <30 mL/min/1.73m²), and hypoglycemia risk. A UACR (urine albumin-to-creatinine ratio) is often ordered at the same visit to screen for diabetic nephropathy per ADA microvascular complication guidelines [7].

Step 4. Receive your prescription electronically. Nevada pharmacies accept e-prescriptions via Surescripts. Your provider can route the prescription to any Nevada-licensed retail pharmacy or mail-order pharmacy of your choice.

Step 5. Coordinate prior authorization if needed. Most commercial plans and Nevada Medicaid managed-care plans require prior authorization (PA) before covering Lantus. Your telehealth provider can submit the PA paperwork the same day as your visit, but approval typically takes 3, 10 business days [8].

A 2022 study in JAMA Internal Medicine found that telehealth diabetes visits produced A1C reductions comparable to in-person visits (mean difference 0.03 percentage points; 95% CI -0.14 to 0.20), supporting the clinical adequacy of remote management [9].

Labs Required Before Starting Lantus in Nevada

Starting glargine without baseline labs is clinical malpractice. Your Nevada prescriber, whether in-person or telehealth, will order some or all of the following before writing the first prescription.

A1C (glycated hemoglobin). This is the single most important test. The ADA defines diabetes as A1C ≥6.5% on two separate occasions [2]. It also sets the population-level treatment target of <7% for most adults, though individualized targets may range from <6.5% to <8% depending on hypoglycemia risk and life expectancy [2]. A Quest Diagnostics or LabCorp draw, ordered via your telehealth provider and completed before the visit, is the cleanest workflow.

Fasting plasma glucose (FPG). FPG ≥126 mg/dL on two occasions confirms diabetes per ADA criteria [2]. This value also anchors initial dose titration.

Comprehensive metabolic panel (CMP). Renal function (serum creatinine, BUN, eGFR) is critical because insulin clearance changes with renal impairment. Liver function tests rule out hepatic conditions that alter glucose metabolism. Electrolytes, including potassium, matter because insulin drives potassium intracellularly and hypokalemia can worsen with insulin initiation [10].

C-peptide and anti-GAD antibodies (for new diagnoses). Distinguishing type 1 from type 2 diabetes changes the prescribing strategy substantially. A C-peptide <0.6 ng/mL in the context of hyperglycemia strongly suggests type 1 [11].

Lipid panel and urine albumin-to-creatinine ratio (UACR). Both are recommended by the ADA at diabetes diagnosis and annually thereafter to assess cardiovascular and renal risk [2].

Thyroid-stimulating hormone (TSH). Hypothyroidism affects insulin sensitivity and is more common in patients with autoimmune type 1 diabetes. The ADA recommends TSH screening at type 1 diagnosis [2].

Most Nevada commercial labs (Quest, LabCorp, ARUP) can process a standard diabetes panel within 24 to 72 hours.

Transferring an Existing Lantus Prescription to Nevada

Moving to Nevada with an active Lantus prescription from another state is straightforward. Under Nevada Revised Statutes 639.266, a licensed Nevada pharmacist may dispense a prescription issued by an out-of-state prescriber if the prescription meets Nevada's labeling and documentation requirements and the out-of-state prescriber holds a license in their home state [5]. For controlled substances this process is more restricted, but insulin is not a controlled substance.

Practical steps:

1. Call your new Nevada pharmacy (Walgreens, CVS, Smith's Pharmacy, or an independent) and provide the prescription number from your previous state.
2. The Nevada pharmacy contacts the originating pharmacy directly via fax or Surescripts transfer.
3. The transfer is limited to the remaining authorized refills. If your prescription has zero refills remaining, you need a new prescription from a Nevada-licensed provider.

Your previous out-of-state insurer may not have a Nevada in-network pharmacy. Contact your plan's member services before the transfer to confirm network status and whether a 90-day mail-order supply is cheaper than local fills.

Prior Authorization for Lantus in Nevada: What Documentation You Need

Prior authorization is the single biggest delay most Nevada patients face when starting Lantus. Nevada's largest commercial insurers (UnitedHealthcare, Anthem Blue Cross Blue Shield of Nevada, Aetna, and the Nevada Medicaid managed-care plans operated by Anthem and SilverSummit) all require PA for brand-name Lantus in patients who have not first tried a biosimilar or interchangeable product [8].

Standard PA documentation checklist:

• Diagnosis code (E10.x for type 1, E11.x for type 2) from the medical record
• Current A1C result with date of draw
• Documentation that the patient has tried (or has a contraindication to) at least one biosimilar glargine product, typically Basaglar (insulin glargine-aabc) or Rezvoglar (insulin glargine-aglr)
• Prescriber's clinical justification if a biosimilar is contraindicated
• For type 2 patients on commercial plans: documentation that metformin and at least one additional oral agent were tried and either failed or were contraindicated, per many step-therapy protocols [8]

Nevada law (SB 509, enacted 2021) includes a step-therapy override provision. If your physician documents that the required step-therapy drug is contraindicated or clinically inappropriate, the insurer must respond to the override request within 72 hours for urgent cases and 30 days for standard cases [5].

Insurance denials can be appealed. The Nevada Division of Insurance handles external reviews when internal appeals fail, and patients have 60 days from denial to request an external review [5].

Nevada Medicaid note. As of July 2025, Nevada Medicaid's preferred drug list does not cover Lantus (brand) for either type 1 or type 2 diabetes. Medicaid does cover biosimilar glargine products and other basal insulin analogs. If you are on Nevada Medicaid, ask your provider to prescribe the preferred biosimilar, or work with your prescriber on a PA for medical necessity.

Nevada Pharmacy Options for Filling Lantus

Retail chains. Walgreens, CVS, and Smith's Food and Drug (Kroger-affiliated) are the three largest retail pharmacy chains in Nevada by store count. All three carry Lantus SoloStar pens (3 mL, 100 U/mL) and Lantus vials (10 mL, 100 U/mL). Toujeo SoloStar (insulin glargine 300 U/mL, also Sanofi) is stocked at most locations.

Mail-order. OptumRx, Express Scripts, and CVS Caremark all ship to Nevada addresses. A 90-day supply through mail-order typically costs 15 to 30% less in copay than three monthly retail fills on commercial plans.

503A compounding pharmacies in Nevada. Nevada-licensed 503A compounding pharmacies may prepare patient-specific insulin glargine formulations when a licensed prescriber issues a valid non-sterile or sterile compounding prescription. This is most relevant for patients who need a concentration not commercially available (e.g., U-500 glargine for extreme insulin resistance) or who have documented excipient allergies. The Nevada State Board of Pharmacy maintains the current list of licensed compounding pharmacies at pharmacy.nv.gov [5]. Note that 503A compounded insulin is not FDA-approved and cannot be substituted for commercially manufactured Lantus without prescriber authorization.

Cost without insurance. The cash price for a 10 mL vial of Lantus at Nevada retail pharmacies runs approximately $290, $330 as of mid-2025. GoodRx coupons can reduce this to roughly $175, $210 at participating pharmacies. Sanofi's Insulins Valyou Savings Program caps out-of-pocket cost at $99 per month for eligible uninsured or underinsured patients [12].

Cost Assistance and Patient Support Programs

Insulin affordability remains a documented barrier to adherence. A 2021 Health Affairs analysis found that 1 in 4 U.S. adults with diabetes reported rationing insulin due to cost, a practice associated with diabetic ketoacidosis hospitalization risk [13]. Nevada patients have several concrete options.

Sanofi Insulins Valyou Savings Program. Uninsured patients pay $99 per month for up to 10 packs of Sanofi insulin. Enrollment is at insulinvalyou.com and requires proof of U.S. residency and income documentation [12].

340B-eligible clinics. FQHCs and other 340B-participating health centers in Nevada purchase drugs at significantly reduced prices and pass savings to uninsured or underinsured patients. Nevada Health Centers, Inc. operates 340B programs at multiple rural sites [6].

Nevada Medicaid (for biosimilar glargine). If you qualify for Nevada Medicaid, biosimilar glargine (Basaglar or Rezvoglar) is covered without PA for most beneficiaries. Income eligibility thresholds for adults are 138% of the federal poverty level ($20,783 for a single adult in 2025) [14].

Manufacturer coupons for commercially insured patients. Sanofi's Lantus savings card can reduce commercial plan copays to as low as $0, $10 per fill for eligible patients. The card is not valid for Medicare, Medicaid, or TRICARE beneficiaries [12].

Monitoring and Follow-Up After Starting Lantus in Nevada

Starting glargine is the beginning, not the endpoint. The ADA Standards of Medical Care in Diabetes, 2024 edition, recommends A1C measurement every 3 months until the target is stable, then every 6 months [2]. Your Nevada provider, whether telehealth or in-person, should schedule a follow-up visit 4 to 6 weeks after initiation to review fasting glucose logs and adjust dose.

The standard titration algorithm from the ADA and the American Association of Clinical Endocrinology (AACE) suggests increasing the glargine dose by 2 units every 3 days if fasting glucose consistently exceeds 130 mg/dL, and decreasing by 2 units if fasting glucose falls below 80 mg/dL on two or more occasions [15]. Symptomatic hypoglycemia (glucose <70 mg/dL with symptoms) requires immediate dose reduction and a same-day call to your provider.

Continuous glucose monitoring (CGM) devices such as the Dexterity Libre 3 or Dexterity G7 are now covered by most Nevada commercial plans and Medicare Part B for patients on basal insulin. CGM data can be shared with your telehealth provider via the device app, reducing the need for in-person visits [9].

Annual monitoring targets per ADA 2024 for patients on basal insulin include A1C <7%, time-in-range ≥70% on CGM (70 to 180 mg/dL), blood pressure <130/80 mmHg, and LDL-C <70 mg/dL in patients with established ASCVD [2].